DVA 📈 DaVita HealthCare Partners - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23918K1088

DVA: Kidney Dialysis, Lab Services, Hemodialysis, Clinical Research, Physician Services

DaVita Inc. is a leading provider of kidney dialysis services, catering to patients with chronic kidney failure in the United States. The company's extensive network of outpatient dialysis centers offers a range of services, including hemodialysis, which can be administered on an outpatient, hospital inpatient, or home-based basis. Additionally, DaVita operates clinical laboratories that conduct routine laboratory tests for dialysis patients, as well as other physician-prescribed tests for individuals with end-stage renal disease (ESRD). The company's management and administrative services support the efficient operation of outpatient dialysis centers, ensuring that patients receive high-quality care.

DaVita's service portfolio extends beyond dialysis, with the company offering integrated care and disease management services to patients participating in risk-based and other integrated care arrangements. This comprehensive approach enables patients to receive coordinated care, addressing their unique needs and promoting better health outcomes. Furthermore, DaVita engages in clinical research programs, providing valuable insights into the management of kidney disease and related conditions. The company's physician services and comprehensive kidney care services round out its offerings, making it a one-stop solution for patients requiring kidney care. DaVita also provides acute inpatient dialysis services, related laboratory services, and operates a transplant software business, underscoring its commitment to delivering a broad spectrum of kidney care services.

With a history dating back to 1994, DaVita Inc. has established itself as a prominent player in the healthcare industry, particularly in the realm of kidney care. The company's name change from DaVita HealthCare Partners Inc. to DaVita Inc. in September 2016 reflects its evolving focus and commitment to delivering high-quality patient care. Headquartered in Denver, Colorado, DaVita Inc. is a publicly traded company, listed on the New York Stock Exchange (NYSE) under the ticker symbol DVA. Its common stock is classified under the GICS Sub Industry of Health Care Services, with the ISIN code US23918K1088. For more information, investors and patients can visit the company's website at https://www.davita.com.

Additional Sources for DVA Stock

DVA Stock Overview

Market Cap in USD 12,528m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Services
IPO / Inception 1995-10-31

DVA Stock Ratings

Growth 5y 59.2%
Fundamental 46.0%
Dividend -
Rel. Strength Industry 798
Analysts 3.11/5
Fair Price Momentum 160.06 USD
Fair Price DCF 448.24 USD

DVA Dividends

No Dividends Paid

DVA Growth Ratios

Growth Correlation 3m -25.6%
Growth Correlation 12m 90.6%
Growth Correlation 5y 44.6%
CAGR 5y 15.35%
CAGR/Mean DD 5y 0.92
Sharpe Ratio 12m 1.28
Alpha 23.37
Beta 0.82
Volatility 29.09%
Current Volume 1793.3k
Average Volume 20d 738.7k
What is the price of DVA stocks?
As of December 22, 2024, the stock is trading at USD 151.85 with a total of 1,793,318 shares traded.
Over the past week, the price has changed by -0.58%, over one month by -5.92%, over three months by -7.41% and over the past year by +46.19%.
Is DaVita HealthCare Partners a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, DaVita HealthCare Partners (NYSE:DVA) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 46.00 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DVA as of December 2024 is 160.06. This means that DVA is currently overvalued and has a potential downside of 5.41%.
Is DVA a buy, sell or hold?
DaVita HealthCare Partners has received a consensus analysts rating of 3.11. Therefor, it is recommend to hold DVA.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 5
  • Sell: 2
  • Strong Sell: 0
What are the forecast for DVA stock price target?
According to ValueRays Forecast Model, DVA DaVita HealthCare Partners will be worth about 172.9 in December 2025. The stock is currently trading at 151.85. This means that the stock has a potential upside of +13.84%.
Issuer Forecast Upside
Wallstreet Target Price 156.9 3.3%
Analysts Target Price 113 -25.6%
ValueRay Target Price 172.9 13.8%